Cargando…

Reply to: COVID-19 and Coagulopathy

Detalles Bibliográficos
Autores principales:	Rodríguez, Cristina, Luque, Neus, Blanco, Isabel, Sebastian, Laura, Barberà, Joan Albert, Peinado, Víctor I., Tura-Ceide, Olga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456881/ https://www.ncbi.nlm.nih.gov/pubmed/33770453 http://dx.doi.org/10.1165/rcmb.2021-0103LE

Ejemplares similares

Pulmonary Endothelial Dysfunction and Thrombotic Complications in Patients with COVID-19
por: Rodríguez, Cristina, et al.
Publicado: (2021)

Updated Perspectives on Pulmonary Hypertension in COPD
por: Blanco, Isabel, et al.
Publicado: (2020)

Differences and Similarities between the Lung Transcriptomic Profiles of COVID-19, COPD, and IPF Patients: A Meta-Analysis Study of Pathophysiological Signaling Pathways
por: Aguilar, Daniel, et al.
Publicado: (2022)

Atrophy signaling pathways in respiratory and limb muscles of guinea pigs exposed to chronic cigarette smoke: role of soluble guanylate cyclase stimulation
por: Peinado, Víctor Ivo, et al.
Publicado: (2023)

Soluble guanylate cyclase stimulation reduces oxidative stress in experimental Chronic Obstructive Pulmonary Disease
por: Paul, Tanja, et al.
Publicado: (2018)

Progenitor cell mobilisation and recruitment in pulmonary arteries in chronic obstructive pulmonary disease
por: Tura-Ceide, Olga, et al.
Publicado: (2019)

Imbalance between endothelial damage and repair capacity in chronic obstructive pulmonary disease
por: García-Lucio, Jéssica, et al.
Publicado: (2018)

Association Between Systemic and Pulmonary Vascular Dysfunction in COPD
por: Piccari, Lucilla, et al.
Publicado: (2020)

COVID-19 and Coagulopathy
por: Inoue, Ken-ichiro, et al.
Publicado: (2021)

Survivin inhibition with YM155 ameliorates experimental pulmonary arterial hypertension
por: Blanco, Isabel, et al.
Publicado: (2023)

Circulating Progenitor Cells and Vascular Dysfunction in Chronic Obstructive Pulmonary Disease
por: Pizarro, Sandra, et al.
Publicado: (2014)

Cigarette smoke challenges bone marrow mesenchymal stem cell capacities in guinea pig
por: Tura-Ceide, Olga, et al.
Publicado: (2017)

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
por: Zhang, Yan, et al.
Publicado: (2020)

Post-COVID-19 patients show an increased endothelial progenitor cell production
por: Poyatos, Paula, et al.
Publicado: (2022)

Slug Is Increased in Vascular Remodeling and Induces a Smooth Muscle Cell Proliferative Phenotype
por: Coll-Bonfill, Núria, et al.
Publicado: (2016)

Correction: Slug Is Increased in Vascular Remodeling and Induces a Smooth Muscle Cell Proliferative Phenotype
por: Coll-Bonfill, Núria, et al.
Publicado: (2016)

Circulating Cell Biomarkers in Pulmonary Arterial Hypertension: Relationship with Clinical Heterogeneity and Therapeutic Response
por: Tura-Ceide, Olga, et al.
Publicado: (2021)

Protein network analyses of pulmonary endothelial cells in chronic thromboembolic pulmonary hypertension
por: Nukala, Sarath Babu, et al.
Publicado: (2021)

COVID-19 in patients with HIV – Authors' reply
por: Miró, José M, et al.
Publicado: (2020)

Effects of Exercise Training on Circulating Biomarkers of Endothelial Function in Pulmonary Arterial Hypertension
por: Rodríguez-Chiaradía, Diego A., et al.
Publicado: (2023)

Endothelial Dysfunction and Cardiovascular Risk in Obstructive Sleep Apnea: A Review Article
por: Peracaula, Miriam, et al.
Publicado: (2022)

COVID-19 and myocardial infarction – Authors' reply
por: Katsoularis, Ioannis, et al.
Publicado: (2021)

Pulmonary intravascular coagulopathy in COVID-19 pneumonia – Authors' reply
por: McGonagle, Dennis, et al.
Publicado: (2020)

Derivation and characterisation of endothelial cells from patients with chronic thromboembolic pulmonary hypertension
por: Tura-Ceide, Olga, et al.
Publicado: (2021)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Editorial: Metabolic changes in vascular disorders: A path for early diagnosis and new therapeutic targets
por: Ayyoub, Sana, et al.
Publicado: (2023)

Reply to: “Liver fibrosis and adverse outcomes in COVID-19”
por: Ruiz-Margáin, Astrid, et al.
Publicado: (2021)

Blood Flow Disturbances in Congenital Heart Disease: Is Neuroblastoma Suppressor of Tumorigenicity 1 a Target for Preventing Pulmonary Vascular Remodeling?
por: Tura-Ceide, Olga
Publicado: (2022)

Cancer and COVID-19 – Authors' reply
por: Kuderer, Nicole M, et al.
Publicado: (2020)

Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020)

Reply to: Hypertension and severe COVID-19
por: Shibata, Shigeru, et al.
Publicado: (2023)

Reply
por: Roscam Abbing, Reinout L.P., et al.
Publicado: (2020)

Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

COVID-19 and maternal and perinatal outcomes – Authors' reply
por: Chmielewska, Barbara, et al.
Publicado: (2021)

Conflicting COVID-19 excess mortality estimates – Authors' reply
por: Hay, Simon I, et al.
Publicado: (2023)

Reply to Lipworth and Chan
por: Brusselle, Guy, et al.
Publicado: (2023)

COVID-19 Vasculopathy and Post–COVID-19 Phenomenon: Reply
por: Akgul, Ahmet
Publicado: (2021)

Characterising neuropsychiatric disorders in patients with COVID-19 – Authors' reply
por: Varatharaj, Aravinthan, et al.
Publicado: (2020)

On Ventricular Aneurysms, Thrombi, and COVID-19: Reply
por: Hui, Dawn S., et al.
Publicado: (2021)

Surgical Training in the Era of COVID-19: Reply
por: Fuller, Stephanie
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bfu0f824cv3q7i2tv9t6sr9tne